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Polyethylenimine (PEI) has been described as one of the most efficient cationic polymers for in vitro gene
delivery. Systemic delivery of PEI/DNA polyplexes leads to a lung-expression tropism. Selective in vivo
gene transfer would require targeting and stealth particles. Here, we describe two strategies for chemically
coupling polyethylene glycol (PEG) to PEI, to form protected ligand-bearing particles. Pre-grafted
PEG–PEI polymers lost their DNA condensing property, hence their poor performances. Coupling PEG to
pre-formed PEI/DNA particles led to the expected physical properties. However, low transfection
efficacies raised the question of the fate of excess free polymer in solution. We have developed a
straightforward a purification assay, which uses centrifugation-based ultrafiltration. Crude polyplexes were
purified, with up to 60% of the initial PEI dose being removed. The resulting purified and unshielded
PEI/DNA polyplexes are more efficient for transfection and less toxic to cells in culture than the crude ones.
Moreover, the in vivo toxicity of the polyplexes was greatly reduced, without affecting their efficacy.
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INTRODUCTION
The cationic polymer polyethylenimine (PEI) has been
described as one of the most potent non-viral gene delivery
vectors in an increasing number of invitro, as well as invivo
studies (Abdallah et al., 1995; Boussif et al., 1995; Goula
et al., 1998a; Coll et al., 1999; Aoki et al., 2001). PEI is
used for systemic delivery (Goula et al., 1998a; Bragonzi
et al., 2000; Zou et al., 2000), and found that, linear PEI
(L-PEI) was much more potent than branched PEI (B-PEI).
However, ca. 95% of transgene expression was found in the
lungs (Goula et al., 1998a; Bragonzi et al., 2000). The
mechanism by which this “non-specific targeting” occurs is
still under investigation (Goula et al., 2000; Chollet et al.,
2001). As intravenous injection should be a route of choice
for delivering genes in many therapeutic applications,
several attempts, including ours, have been made to target
in vivo ligand-derivatized PEI/DNA polyplexes to
several organs or cell types (Erbacher et al., 1999b; Li
et al., 2000). Although we were able to show that ligand-
modified PEI/DNA polyplexes transfect the corresponding
receptor-expressing cells in vitro, with efficacies much
higher than those of native polymers (Kircheis et al., 1997;
Zanta et al., 1997; Erbacher et al., 1999b), none of these
formulations showed positive results following intra-
venous injection. It is generally accepted that polyplexes
for i.v. delivery should possess two well-defined physico-
chemical properties: (i) a size below 100 nm, in order to
facilitate extravasation and diffusion within organs (Goula
et al., 1998b); (ii) a neutral/negative surface charge, to
prevent RES clearance (Plank et al., 1996; Ogris et al.,
1999). This implies to replace electrostatic interactions
with the cell surface interactions, and to coat the complexes
with a protective hydrophilic shell. Polyethylene glycol
(PEG) is the most commonly used polymer for this purpose
(Ogris et al., 1999; Finsinger et al., 2000).
We previously showed that polyethylene glycol grafting
to branched PEI was interfering with proper DNA conden-
sation into compact particles (Erbacher et al., 1999a).
To circumvent this problem, we describe here a post-
grafting strategy, in which PEG or ligand – PEG
residues are conjugated to preformed B- or L-PEI/DNA
spherical polyplexes. Their physical characteristics
(i.e. morphology, size and surface charge) were as
anticipated, yet low transfection efficacies raised the
question of excess free ligand– PEG– PEI polymer
molecules that would compete with the polyplexes for
receptor binding.
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We, therefore, separated the polyplexes from excess
polymer and found that, at nitrogen per phosphate (N/P)
ratios used for transfection, up to 50% of the cationic
polymer was indeed free in the solution. Characterization
of purified PEI/DNA polyplexes, as well as comparative
in vitro toxicity and gene transfer data are described.
Finally, a preliminary in vivo experiment using unshielded
and purified polyplexes showed lower toxicity, without
expense on vector efficacy.
RESULTS
Structure of Crude PEGylated PEI/DNA Complexes
B-PEI was pre-grafted with increasing PEG3400 amounts,
to an extent corresponding to an equivalent of 0.5 to 4% of
the PEI’s total nitrogen atoms (2.5–20 PEG molecules per
PEI). At any grafting extent, PEG–PEI conjugates lost
their ability to properly condense DNA. Instead of
condensing DNA, PEG–PEI polymers formed tangles of
strings upon complexation with DNA (Fig. 1A). These
particles, were electrostatically neutral and unable to
transfect cells. With the aim of forming compact
complexes, L-PEI was mixed with plasmid DNA prior to
chemical coupling to PEG, by the formation of a carbamate
linker (Bettinger et al., 1998). As expected, transmission
electron microscopy showed toroids and rods, but also
loops extending out of condensed cores (Fig. 1B); the
proportion of the later being related to the PEG grafting
extent (data not shown). The same type of post-grafted
particles was also prepared with B-PEI and showed
relatively calibrated spherical structures, but with less
loops (data not shown). Laser light scattering measure-
ments, i.e. size and zeta potential, were in agreement with
these observations, both showing small and neutral
particles. However, optimized in vitro transfection using
those post-grafted particles gave up to a hundred-fold
higher reporter gene expression than the pre-grafted ones
(104–107 RLU/mg proteins with a pCMV-luciferase
encoding plasmid, HeLa cells, TB, unpublished results).
Aggregation Properties of Crude Post-grafted
Polyplexes
Small L-PEI/DNA particles were prepared in 5% glucose
solution (Goula et al., 1998b). Albeit stable under
this condition, the polyplexes aggregated if serum-albumin
was added (Fig. 2A). Maximal aggregation was obtained
between 1 and 2 mg/ml albumin. At higher concentrations,
zeta potential became strongly negative (220 mV; data not
shown) indicating that albumin had completely coated the
particles and excess of protein prevented aggregation.
We then challenged particles towards aggregation
induced by 1mg/ml albumin and physiological saline
concentration (Fig. 2B–D). Native L-PEI was found to be
very sensitive to both conditions, with micron-range
aggregates formed within minutes. PEG600 post-grafted
polyplexes were still sensitive, although kinetics of
aggregation were shifted to hours. Finally, PEG3400 post-
grafted complexes became completely protected towards
both salt- and protein-induced flocculation.
Complement System Activation
Post-grafted L-PEI/DNA particles were further challenged
by an in vitro assay of complement system activation,
described earlier (Plank et al., 1996). In Fig. 3,
%CH50max, which is inversely proportional to comple-
ment system activation was plotted against the PEI nitrogen
concentration. Native L-PEI strongly activated the
complement system. Increasing the molecular weight
and/or the extent of PEG grafting reduced complement
activation down to undetectable levels with 7% PEG3400,
independently of the chemical nature of the ligand grafted
at the PEG distal end (RGD peptide vs. galactose).
Formulation of DNA with the Branched 25 kDa PEI
into Small Particles
Plasmid DNA mixed with 25 kDa B-PEI formed large
aggregates under physiological conditions (150mM NaCl)
at N/P ratio #5. Smaller particles (100–200 nm) were
obtained at higher N/P ratios (10–20), but the size remained
above 100 nm. Changing the complex formation medium
to 20mM HEPES buffer pH 7.4, significantly decreased
both the size and polydispersity of the particles (Fig. 4).
Sedimentation Properties of PEI/DNA Complexes
When plasmid DNAwas formulated with 22 kDa L-PEI in
5% glucose, small (30–100 nm) spheroidal particles were
produced (Goula et al., 1998b). We performed sedimenta-
tion experiments with 32P-labeled DNA in conditions
allowing the preparation of small particles either with the
B- (in 20 mM HEPES pH7.4) or the L-PEI (in 5%
glucose). PEI/DNA complexes made at several N/P ratio
were centrifuged at various speed (20 to 10,000g) for
10 min. Irrespective of the N/P ratio, the amount of
sedimented DNA was found less than 20 and 25% for
polyplexes prepared with L- and B-PEI, respectively
(Fig. 5A and C).
Purification of the PEI/DNA particles by ultrafiltration,
required a high DNA concentration (200mg/ml) and a low
centrifugation speed (500 g). Three centrifugation cycles
(10 min at 500 g) were performed on both L- and B- PEI
complexes (Fig. 5B and D). The proportion of DNA found
in the pellet was #20 and 30% at N/P $ 5, respectively.
Isolation of Genuine PEI/DNA Particles by
Ultrafiltration:
Removal of excess free polymer in polyplex formulations,
was performed by ultrafiltration through Centricon-100
filters. Control experiments showed that PEI/32P-DNA
complexes mostly (.70% at N/P $ 8) remained in
the supernatant after three centrifugation cycles
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(500g, 10 min) and could be recovered (Fig. 6A and B).
Low amounts (#20% at N/P $8) of particles stuck to the
filter, and some radioactivity, that may be attributed to
traces of 32P-labeled nucleotides coming from the labeling
procedure, went through the filter. We also verified that
both forms of PEI entirely passed through the filter, using
fluorescent polycations and that naked DNA was totally
recovered in the supernatant (Fig. 6C). After ultrafiltra-
tion, the free polymer was recovered in the filtrate
(Fig. 6D). As expected, the amount of free PEI increased
with the N/P ratio used to prepare complexes and
reached values of about 50% at N=P ¼ 10 for both PEIs.
Determination of DNA amounts recovered after
the ultra-filtration showed that more than 70% of total
plasmid DNA was present and that only a low quantity of
DNA precipitated on the filter.
Physical Characteristics of the Purified Polyplexes
Particle size measurements done by DLS (Fig. 7) showed
that the purification protocol at worst increased the particle
size by 10–30 nm. Moreover, the solutions remained
mono-disperse and stable over several days. At the end of
each cycle of centrifugation, the volume of the DNA-
containing solution was reduced by 10. So this purification
procedure represents also a mean to quickly prepare
FIGURE 1 Transmission electron micrograph (TEM) of polyplexes (50mg of pCMVLuc; N=P ¼ 5) prepared with 25 kDa B-PEI-PEG3400-Gal 4%
conjugates following the PEI pre-grafting strategy (A) and post-grafted 22 kDa L-PEI/DNA polyplexes (50mg of pCMVLuc in 1ml of a 5% glucose
solution; N=P ¼ 5) with 2.5% Gal-PEG3400-SC derivative (B). Bars indicate 100 nm.
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stable, small and highly concentrated DNA-containing
particles (up to 4mg/ml DNA). The size range of the
purified particles was confirmed by electron microscopy
(Fig. 8).
Cytotoxicity and Transfection Efficiency of Pure
Polyplexes
The in vitro polymer-associated toxicity in the absence of
DNA was determined using the MTT assay (Fig. 9).
For N/P ratios 1–20 (6–120mM), B-PEI showed low
toxicity (viability .80%). Depending on the cell line,
L-PEI appeared more toxic. On HeLa cells, less than 50%
of the cells remained viable 24 h after incubation with
L-PEI at N=P ¼ 20: For B-PEI, the LD50 was reached for
300 (N=P ¼ 50; 13mg/ml), 600 and 900mM polymer on
HeLa, 3T3, and BNL.CL2 cells, respectively. For L-PEI,
LD50 was reached for 90, 300 and 300mM on HeLa, 3T3,
and BNL.CL2 cells, respectively.
Using 2mgDNAfor transfection (Fig. 10A–D), luciferase
gene expression showed a slight increase with genuine
PEI/DNA complexes vs. the crude ones. This effect may be
related to the slight viability increase obtained with purified
complexes (especially for L-PEI). Increasing the DNA dose
used for transfection enhanced the differences between pure
and crude complexes (Fig. 10E–H). A strong toxicity was
observed using 10mg DNA with the crude complexes
whereas cell viability was unchanged with pure particles.
To confirm the deleterious effect of free PEI, pure
polyplexes were re-mixed with some free polymer and
added to the cells (Fig. 11). Transfection efficiency and
FIGURE 2 Behaviour of unpurified 22 kDa L-PEI/DNA polyplexes and post-grafted polyplexes, in the presence of albumin and under physiological
saline concentration. (A) Mean size of polyplexes as a function of albumin concentration. (B–D) Polyplexes were prepared at N=P ¼ 5 and 20mg/ml
DNA, either in water (circle), waterþ 1mg/ml albumin (lozenge) or 150mMNaCl (filled square). The polyplex sizes were determined by dynamic light
scattering after 30min of incubation.
FIGURE 3 Activation of the complement system as a function of
polymer amine concentration. Low values represent high activation, see
Plank et al., (1996) for experimental conditions.
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the cell survival markedly decreased with increasing
amounts of free PEI.
Gene Delivery with the Pure Complexes Following
Intravenous Injection
It was shown that L-PEI confers a lung-expression tropism
to plasmid DNAwhen injected into the mouse tail vein in
a 5% glucose solution (Goula et al., 1998a; Zou et al.,
2000). Optimal transfection conditions were obtained by
injecting complexes prepared at N=P ¼ 10; hence
containing a large excess of PEI (60%). A 40- to 50-fold
decrease in gene expression in the lung was observed for
N=P ¼ 4; i.e. when most of the polymer is associated with
DNA. We, therefore, decided to inject the purified
complexes containing 50mg DNA at an initial ratio of
N=P ¼ 10: A 6-fold decrease of gene expression was
obtained in the lungs compared to the unpurified
complexes. Increasing the DNA dose to 100mg reduced
the difference of efficiency between pure and crude
particles. At 150mg DNA, only pure complexes allowed
gene expression whereas the mice died within hours with
the crude complexes.
Influence of the Purification of Polyplexes on PEG
Grafting Yields
Table I shows the grafting extent, as percentage of the total
amine content (i.e. amino groups of PEI), after a coupling
reaction between a reactive PEG and polyplexes, in three
situations: pre- and post-grafting using the crude
polyplexes, as well as post-grafting using the pure
polyplexes. For comparative purposes, the amounts
of PEI, DNA and PEG were the same. After 24 h,
the non-reacted PEG was removed by extensive dialysis
against water. The molecular weight cut-off of the
membrane did not allow free PEG–PEI or PEI molecules
to diffuse out. The final reaction yield was determined as
described in the “Material and Methods Section”,
and showed a clear dependency on the presence of
free polymer molecules, as is dropped from 3.9 down
to 1.5%.
FIGURE 4 B-PEI/DNA complexes (25 kDa) have different sizes according to the formulation conditions. Complexes were prepared in 20mMHEPES
pH 7.4 (A) filled circles; (B) lower panel, or in 150mMNaCl solution (A) open circles; (B) upper panel. (A) Thirty minutes after complex formation, the
particles sizes were determined by dynamic light scattering. (B) Transmission electron microscopy. Bars indicate 100 nm.
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FIGURE 5 Sedimentation of radio-labeled polyplexes in microcentrifuge tubes. (A) Single centrifugation of 10min. (B) Three cycles of centrifugation
at 500g for 10 min each.
FIGURE 6 Purification of PEI/DNA polyplexes, ultra-filtered 3 times at 500g for 10 min. (A and B) PEI/32P-labeled polyplexes. Supernatants, filters, and
filtrates (pooled) were counted separately. (C) Percentage of FITC-labeled PEIs (fluorescence; 1.5mmol corresponding to N/P5 with 100mg DNA) or free
DNA (OD260 nm; 100mg pCMV-Luc) passing through the filter unit. (D) Percentage of the PEI dose removed after filtration, as a function of the starting N/P
ratio. The amount of PEI that passed through the filter was measured by standard ninhydrin and TNBS assays.
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FIGURE 8 TEM of 22 kDa L-PEI (A, C) and 25 kDa (B, D) polyplexes ðN=P ¼ 10Þ; before (A, B) and after (C, D) purification.
FIGURE 7 Dynamic light scattering size determination of polyplexes before (open circles) and after (closed circles) purification.
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DISCUSSION
Systemic delivery of DNAvectors has received increasing
interest, as diffusion of particles within tissues was
recognized as being a physical barrier. However, results
obtained so far for cationic polymer/DNA complexes were
disappointing (Wolfert et al., 1996; Ogris et al., 1999;
Nguyen et al., 2000; Benns et al., 2001; Blessing et al.,
2001). In fact, biological properties of polyplexes are
strongly related to their physico-chemical properties,
namely their size, morphology, surface charge and
colloidal stability (Tang and Szoka, 1997; Ogris et al.,
1998; Erbacher et al., 1999a; Wightman et al., 2001).
Over the years, we succeeded in preparing small
L-PEI/DNA particles that were effective in vivo (Goula
et al., 1998b). However, their lung-expression tropism,
being due to a bolus effect (Zou et al., 2000), the need for
vectors that could form “stealth” complexes with DNA, in
order to prevent their clearance by the reticulo-endothelial
system, became obvious. This has already been achieved
in the nanoparticle and liposome fields, by grafting
polyethylene (glycol) onto the surface of the vehicles
(Allen et al., 1991; Papahadjopoulos et al., 1991; Woodle
et al., 1992; Zalipsky et al., 1994). Recent studies have
also described PEGylated cationic polymer systems, some
of them reporting promising in vivo results (Ogris et al.,
1999; Kircheis et al., 2001). However, the chemistries
used and the lack of purification led to rather loosely
characterized delivery systems.
Pre-grafted PEG–PEI/DNA polyplexes displayed very
attractive physical characteristics, as light scattering and
zeta potential measurements gave values corresponding
to small (30 nm) and neutral particles (Erbacher et al.,
1999a). Electron micrographs were in contradiction with
the indirect sizing technique. In fact, random grafting of
2–10 PEG3400 molecules on each PEI polymer seems to
interfere with its DNA condensing ability. Assuming
compact spheroidal particles, the odd scattered light data
were converted by the instrument into small “particles”.
These observations have been also described by Rackstraw
et al. (2001).
We decided to circumvent this interference by directly
attaching the PEG moiety to pre-formed polyplexes.
Amino-hydroxy-PEG3400 was converted to pyridyldithio-
hydroxy-PEG by reaction with the commercially available
SPDP reagent. It was further activated as a succinimidyl
carbonate on its hydroxy terminus by reacting it with the
commercially available DSC reagent. The final hetero-
bifunctional PEG derivative was added to the pre-formed
polyplexes. Reaction between amino groups of the PEI
and functionalized PEG led to pyridyldithio-PEG
coated particles. Thio-galactose or a cystein-containing
RGD peptide (Erbacher et al., 1999b) were further coupled
the distal end, yielding the ligand–PEG-particles. This
three-step protocol allowed the formation of post-grafted
PEGylated and cell-targeting polyplexes. In order to obtain
formulations that are consistent with the biophysical
characteristics required for systemic delivery, we needed to
start with small PEI/DNA complexes. L-PEI was already
shown to form small particles with DNA in 5% glucose
solution. As we found out, B-PEI can form even smaller
particles with DNA if complexes are prepared in low ionic
strength Hepes buffer, at physiological pH. Both L-PEI-
and B-PEI-based particles were post-grafted with PEG.
The resulting complexes displayed no longer “hair-like”
structures, but rather spherical, toroidal or rod-like ones.
These structures were already observed with other vectors,
such as chitosan (Erbacher et al., 1998), and were shown
to be compatible with gene delivery. In most cases
however, some 5–10 nm-thick strains were seen looping
out of the complexes.
The resistance to salt- and protein-induced aggregation
and to complement activation are challenges in the
formulation of vectors displaying the desired steric stability
FIGURE 9 Cell viability as a function of free PEI dose (expressed as
“pseudo N/P ratio with 2mg DNA” and mg/ml). Cells were cultured in
24-well tissue culture plate in 1ml of 10% serum-containing medium and
cell viability was measured after 24 h by the MTT assay (n ¼ 4; ^ S.D.).
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and inertness under physiological conditions (Finsinger
et al., 2000). The chosen post-grafting strategy proved
successful in that PEG of high molecular weight was able to
protect polyplexes under conditions mimicking systemic
delivery. Together with higher in vitro transfection
efficiencies, as compared to the pre-grafted particles,
these results were encouraging. However, PEG post-
grafted polyplexes proved to be unable to deliver genes in
vivo, whether targeting cells or not (RGD–PEG–
PEI/pCMV–Luc injected in tumor-bearing mice, JLC
unpublished data). Moreover, the in vitro transfection
levels were neither depending on the presence, nor on
FIGURE 10 Transfection efficiency and cell viability of purified (filled bars) and unpurified (hatched bars) polyplexes, as a function of N/P ratio with
2mg/well DNA (A–D) or DNA dose at N=P ¼ 10 (E–H). Transfections (24-well tissue culture plate; 1ml of 10% serum-containing medium ) were
performed for 24 h with pCMV-Luc plasmid and gene activity was expressed as relative light units integrated over 10 s, per well, ^ S.D. ðn ¼ 3Þ: Cell
viability was measured after 24 h by the MTT assay (n ¼ 3; ^ S.D.).
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the nature of the ligands, irrespective of the transfected cell
type (TB and PE, unpublished results).
This strongly suggested that the amount of PEI used for
vector formulation was not entirely incorporated into
vector particles and remained either free, or loosely bound
to particles. This excess PEI would be disadvantageous in
a post-grafting strategy and may even prove inhibitory in
a combined post-grafting and targeting approach. There-
fore, we went back to unmodified PEIs, and developed a
protocol to remove potentially “free” cationic polymers.
Ultra-filtration through molecular weight cut-off mem-
brane embedded into centrifuged device for centrifuga-
tion-accelerated filtration seemed to be the most
convenient technique. We first verified that small
polyplexes did not sediment under the chosen conditions.
In fact, at any speed up to 10,000 g, not more than 20% of
the particles were sedimented, in a microcentrifuge tube
assay. We also verified that polyplexes were behaving
properly under the conditions used for purification
(3 cycles of 10 min at 500 g; Figs. 5B,D, and 6A,B), and
that free PEI molecules were passing through the filter
membrane, in contrast to plasmid DNA (Fig. 6C). We then
ran the purification protocol on polyplexes. The
proportion of free PEI depended on the initial N/P ratio
and on the PEI structure (linear vs. branched; Fig. 6D).
The data can be interpreted such that roughly up to 2–3
FIGURE 11 Transfection efficacy and cell viability as a function of free 22 kDa L-PEI. Polyplexes were prepared at an initial N=P ¼ 10 and subjected
to purification to obtain a final N=P ¼ 5: Purified polyplexes corresponding to 2mg DNA were added in each well (triplicates), together with various
amounts of free PEI (expressed as N/P ratios equivalent to polyplexes prepared with 2mg DNA). added to 22 kDa L-PEI/DNA purified complexes (initial
N=P ¼ 10). Added free PEI is expressed as “pseudo equivalents”. Transfection efficiency and cell viability are expressed as percentage of the maximal
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P. ERBACHER et al.232
L-PEI and 4–5 B-PEI equivalents (in terms of the N/P
ratio) can tightly bind to DNA and stay in the core of the
complex, whatever the initial PEI input was; above this,
the remaining polymer being free in solution. However,
the initial high input of polymer is vital for the formation
of small polyplexes. Interestingly, once the complexes are
formed at a high input ratio, the removal of free PEI does
not alter the physical characteristics of L- and B-PEI/DNA
particles (Figs. 7 and 8), except the zeta potentials that
were slightly lower (ca. 10 mV; data not shown) at their
cationic plateau. It is also remarkable that during the
purification protocol, particles were concentrated up to
4 mg DNA per ml, a fact that might be of interest for some
in vivo transfection protocols.
PEI, just like other cationic polymers, is toxic to cells,
when added as a free molecule. The LD50’s depend on the
cell type and polymer structure. However, the polymer
concentrations that are toxic are much higher than those
commonly used in in vitro gene delivery (Fig. 9), except
for 22 kDa L-PEI on HeLa cells. Yet, this does not rule out
a synergistic toxicity effect between polyplexes and free
polymer molecules. In fact, this is exactly what is
observed in vitro (Fig. 10). Comparing pure and
crude complexes as a function of N/P ratio clearly
shows that pure particles exhibit transfection efficacies
ranging from similar to 10-fold better. Along the
same line, cell viability is sometimes increased when
pure particles were used. Using escalating doses of
polyplexes further supported this finding: pure particles
are less toxic and more efficient than crude ones, the later
effect being possibly a consequence of the former.
This was confirmed by adding back free polymers to the
pure complexes, just before transfecting cells. The results
shown in Fig. 11 undoubtedly confirm the deleterious
effect of free polymer on both cell viability and transgene
expression levels.
In a preliminary set of in vivo experiments, we
injected mice in the tail vein with polyplexes
prepared at N=P ¼ 10; in 3 escalating doses (50, 100
and 150mg DNA), with either pure or crude non-grafted
polyplexes. Although it is too early to draw final
conclusions, there was a clearly toxic effect of crude
complexes at the highest dose, that was not observed with
the pure complexes.
Coming back to the preparation of “stealth” polyplexes
for in vivo experiments, we compared the extent of PEG
grafting on three types of formulations (Table I). The pre-
grafting strategy is a “regular” chemical reaction, in which
free molecules are coupled together. We obtained 11% of
PEG grafting to PEI. Quantitative reaction would have led
to 50% grafting, i.e. the chemical coupling yield was ca.
20%. Post-grafting the pure pre-formed polyplexes gave
1.5% grafting, which represents a chemical yield of 3%.
It is therefore clear that PEGylation occurs preferentially
(20:3) on free polymer, instead on the particles surface.
As a consequence, published in vivo data using crude
complexes may not be representative of the properties of
pure cationic polymer/DNA complexes.
MATERIALS AND METHODS
Chemicals
Branched PEI (B-PEI, average MW ¼ 25 kDa; average
degree of polymerization ¼ 580) and linear PEI
(L-PEI, average MW ¼ 22 kDa; average degree of
polymerization ¼ 510, Exgen 500) were obtained from
Aldrich (St. Quentin Fallavier, France) and Euromedex
(Souffelweyersheim, France), respectively.
Particle Size and Zeta Potential Measurements
B-PEI-based complexes were prepared in 20mM HEPES
buffer, pH 7.4 and L-PEI-based complexes in a 5%
glucose solution. To 100mg pCMVLuc plasmid in 500ml
solution, the desired amount of PEI in 500ml solution was
added, mixed, and left for 15min at room temperature.
Particle size or zeta potential was measured using a
Zetasizer 3000 (Malvern Instrument, Orsay, France) with
specifications as described previously (Erbacher et al.,
1999a). DNA-containing complexes were also observed
by transmission electron microscopy (TEM), with a
Philips EM 410 transmission electron microscope, as
described previously (Erbacher et al., 1999a).
Synthesis of PEI–PEG-SS-Galactose
HCl·H2N–PEG3400–COOH (Shearwater Corporation,
Huntsville, AL) was first modified to a hetero-
bifunctional HOOC–PEG–SS–Pyridine derivative
before grafting to PEI as previously described (Erbacher
et al., 1999a). The resulting PEI–PEG–SS–Pyridine
conjugate was converted to PEI–PEG–SS–Galactose by
addition of 1-thio-b-D-Galactopyranose (Sigma,
St. Quentin Fallavier, France) as described by Erbacher
et al. (1999a).
Post-grafting of PEI/DNA Complexes with
PEG–ligand Conjugates
L-PEI/DNA complexes (22 kDa) were prepared in 1ml
water (100mg of pCMVLuc; N=P ¼ 5–8). A measured
quantity of 0.6–3mmol of heterobifunctional a-pyridyl-
dithio-v-hydroxy-PEG-succinimidyl carbonate deriva-
tive (Py-SS-PEG600 or 3400-SC, synthesis described in
Bettinger et al. (1998)) were added and the solution
was left 12 h at room temperature. Excess PEG
derivatives were removed by dialysis against water for
two days (MWCO 100,000; Dispodialyser Spectra/Porw).
The post-grafting yield was estimated by release of
2-thiopyridone following reduction with excess DTT
(monitoring at 343 nm). Two PEG3400SS-Py-post-
grafted complexes were prepared, having 2.5 and 7% of
derivatized amine functions. One PEG600SS-Py-post-
grafted complexes was prepared, having 7% of
derivatized amine functions. The final targeted complexes
were obtained after addition of two molar equivalents of
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1-thio-b-D-Galactopyranose or HS-CYGGRGDTP
peptide (Genosys, Cambridge, UK). The reaction
was completed within 30 min, as indicated by the
formation of 2-thiopyridone (about 95% yield). Excess
of low molecular weight ligands were removed by
dialysis against water for two days (MWCO 10,000,
Spectra/por).
DNA Labeling Protocol and Sedimentation
Experiments
pCMVLuc plamid (25 ng) was radiolabeled by random
priming with a Megaprime DNA labeling kit (Amersham,
Les Ulis, France) and [a-32P] dCTP (3000Ci/mmol,
Amersham) yielding to 2.4 £ 109 cpm/mg DNA. The DNA
probe was then added to 250mg unlabeled plasmid giving a
final activity of 9.6 £ 106 cpm/mg DNA. To prepare
complexes, 2mg pCMVLuc and various amounts of
polycation were diluted separately in 100ml 2mM HEPES
pH7.4 (B-PEI), and in a 5% glucose solution (L-PEI), in
prelubricated microcentrifuge tubes (Costar, Cambridge,
MA). After 10min, the vector was added to the DNA; the
resulting solution was homogenized and left for 15min at
room temperature. Complexes were then centrifuged at
various speed (17, 150, 420, 1620, 3770, 6700, 11340g) for
10 min. Supernatants (180ml) and pellets (20ml) were
counted separately in a scintillation counter, using the
Cerenkov procedure. The percentage of sedimented
DNA/polymer complexes was calculated according to the
following formula:
h




Purification of DNA Complexes by Ultrafiltration
Polyplexes (100mg DNA per ml in 20mM HEPES
pH7.4 or 5% glucose solution) were centrifuged
through Centricon-100 membranes (Millipore, Saint-
Quentin, France) 3 times 10min at 500g on a Sigma
K10 fixed angle rotor. Between centrifugations the
polyplex solutions were rediluted to their original
concentrations.
In order to measure the fraction of PEI present in the
PEI/DNA complexes, PEI was labelled with fluorescein
isothiocyanate (Sigma) in a 0.2M borate buffer pH 8.4.
The conjugate was purified by gel filtration on a PD10
column (Sephadex G-25M, Pharmacie Biotech, Sweden)
in water. The concentration of PEI amine functions (N)
was determined with the ninhydrin assay. The level of
fluorescein conjugation per amino group of PEI and
was 1% as measured by absorption spectroscopy at
495 nm. After the polyplex centrifugation step
through Centricon-100 membranes, the amount of free
PEI-fluorescein present in the filtrate was determined by
absorbance at 495 nm, from which the fraction of PEI that
was associated with DNA was calculated.
In Vitro Transfection
HeLa human cervix epitheloid carcinoma (kindly given by
Dr L. Monaco, San Raffaele Scientific Institute, Milan,
Italy) were grown in Minimum Essential Medium (MEM)
with Earle’s salt (PolyLabo, Strasbourg, France) and
supplemented with 10% fetal calf serum (FCS, D. Dutcher,
Brumath, France), 2 mM glutamine (Gibco BRL),
100 units/ml penicillin (Gibco BRL) and 100mg/ml
streptomycin (Gibco BRL). Cells were maintained at
378C in a 5% CO2 humidified atmosphere. The desired
amount of polycation and 6mg of pCMVLuc (for a
triplicate experiment) were diluted separately in 150ml of
20mM Hepes buffer (B-PEI), pH7.4 or in a 5% glucose
solution (L-PEI). After 10min, the polycation was added
to the DNA solution; the mixture was homogenized
and left for 10min. Twenty four hours before transfection,
5–6 £ 104cells/well were seeded in 24-well tissue culture
plates. Before transfection, cells were supplemented with
1ml fresh complete medium containing 10% FCS.
Then, 100ml of polycation/DNA complexes were added
per well and the plates were incubated at 378C for 24 h.
When specified, HeLa cells were transfected in the
absence of serum. In this case, 10% serum was added to
the cells after 2 h of incubation. Luciferase gene
expression was measured using a commercial kit
(Promega, Cergy Pontoise, France) and a luminometer
(Mediators PhL, Vienna, Austria). Results were expressed
as light units integrated over 10 s, per mg of cell
protein using the BCA assay (Pierce, Paris, France).
Each experiment was done in triplicate.
Intravenous Injection of L-PEI/DNA Complexes
in the Mouse Tail Vein
Female Swiss nude mice (4 weeks old, IFFA-CREDO,
Marcy l’Etoile, France) were placed in a restrainer and
200ml of unpurified or purified 22 kDa L-PEI/DNA
complexes/mouse ðn ¼ 3Þ; prepared in a 5% glucose
solution at a N=P ¼ 10; were injected rapidly (5 s) in the
tail vein, using a 1/2 in 26-gauge needle and a 1ml
syringe (Fig. 12). Animals were killed by cervical
dislocation and lungs were collected, washed with PBS,
homogenized, and transferred in 1.5ml microcentrifuge
tubes containing 1ml pre-cooled lysis buffer (Promega).
Homogenized tissues were subjected to a freeze cycle
(2208C) for one day. The homogenates were thawed, left
at room temperature for 30min and then centrifuged at
14,000g for 5 min. Ten microliters supernatant aliquots
were assayed for luciferase activity using a commercial
kit (Promega) and a luminometer (Berthold, Paris,
France). Results were expressed as light units integrated
over 10 s, per mg of cell protein using the BCA assay
(RLU/mg of protein; 2mg of purified firefly luciferase
produced 108 RLU/10 s).
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